Aeolus Pharmaceuticals Inc. announced results from a large study in non-human primates (NHPs) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25% to 50% doubling survival at 180 days after radiation exposure to the lungs. The survival data was presented at an In Process Review (IPR) meeting with the Biomedical Advanced Research and Development Authority (BARDA). The study results will be included in a pre-Emergency Use Authorization (EUA) submission to the FDA.

In mid-August, Aeolus reported that it filed an Investigational New Drug Application (IND) with the Medical Imaging Products Division of the US Food and Drug Administration (FDA) to enable the initiation of a phase 1 study of AEOL 10150 in healthy normal volunteers. AEOL 10150 has previously been tested in two phase 1 studies in ALS patients where it was safe and well-tolerated. AEOL 10150 has also demonstrated efficacy against nerve agents, sulfur mustard gas and chlorine gas.

Aeolus is developing AEOL 10150 for this indication under a five-year contract with BARDA valued at up to $118 million.